Active Stocks
Mon May 27 2024 15:59:11
  1. Tata Steel share price
  2. 175.50 0.40%
  1. NTPC share price
  2. 369.60 -1.40%
  1. State Bank Of India share price
  2. 834.10 0.66%
  1. HDFC Bank share price
  2. 1,527.95 0.75%
  1. ICICI Bank share price
  2. 1,129.15 -0.19%
Business News/ Science / Health/  Bharat Biotech partners with CEPI to develop ‘variant-proof’ COVID-19 vaccine

Bharat Biotech partners with CEPI to develop ‘variant-proof’ COVID-19 vaccine

The international multidisciplinary consortium will constitute of Bharat Biotech, the University of Sydney and ExcellGene SA, Switzerland


NEW DELHI:Hyderabad based pharma giant Bharat Biotech has partnered with an international multidisciplinary consortium and is all set to receive a funding of US $19.3 million for the  the development of a ‘variant-proof’ coronavirus vaccine candidate that will provide protection against SARS-Cov-2 variants and other beta coronaviruses. 

This was announced by Coalition for Epidemic Preparedness Innovations (CEPI) is the ninth programme to be funded by CEPI to advance the development of vaccines that provide broad protection against SARS-CoV-2 variants and other betacoronaviruses. 

“BBIL has successfully commercialized a universal COVID-19 vaccine for adults and children. While current generation of vaccines are safe and effective, against currently known variants, it is imperative that we focus on innovation for multi-epitope vaccines, where a single vaccine can protect against all future variants. Our expertise in product development and innovation, especially with novel adjuvants and platform technologies will add to the strong partnership with CEPI, ExcellGene, and the University of Sydney," Dr Krishna Ella, Chairman & Managing Director, Bharat Biotech said in a statement. 

“In this new vaccine design, modified trimeric spike immunogens will be produced in a robust and scalable process with high purity and yield at low cost, based on a biomanufacturing approach that has provided significant quantities of protein therapeutics to the world," CEPI said in a release. 

The protocol will also be used for the strategy rapid development of broadly protective vaccines against other beta coronaviruses, as well as vaccines against Disease X—unknown pathogens with pandemic potential that emerge in the future. 

The international multidisciplinary consortium will constitute of Bharat Biotech International Ltd, the University of Sydney, Australia and ExcellGene SA, Switzerland.

You are on Mint! India's #1 news destination (Source: Press Gazette). To learn more about our business coverage and market insights Click Here!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 10 May 2022, 07:41 PM IST
Next Story footLogo
Recommended For You